Fig. 2: Overall survival and recurrence-free survival by vaccine regimen. | Nature Communications

Fig. 2: Overall survival and recurrence-free survival by vaccine regimen.

From: Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial

Fig. 2

A Kaplan–Meier curves for OS for all eligible participants (n = 167) by vaccine regimen (HR 0.65, p = 0.08) and B with 95% CI shown in shaded regions, C Landmark analysis for OS at 2.5 years for eligible participants (n = 138) by vaccine regimen (HR 0.52, p = 0.04), D RFS for all eligible participants (n = 167) by vaccine regimen (HR 0.77, p > 0.22). P values are from two-tailed logrank tests. Adjustments were not made for multiple comparisons. Source data are provided as a Source Data file.

Back to article page